ArticleDrug delivery and translational research2026
Translatability of a miniature pig model to predict subcutaneous clinical injection times with a high-volume auto-injector and recombinant human hyaluronidase.
Article in Drug delivery and translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Miniature pigs are an established preclinical model for subcutaneous (SC) drug administration; however, research on the direct translatability of this model is limited. This post hoc analysis of preclinical and clinical data assessed the translatability of performance characteristics of a high-volume auto-injector (HVAI) and SC injection site outcomes from the miniature pig model to humans. An HVAI was developed to subcutaneously administer 10 mL of an antibody solution at a targeted delivery time of ~ 30 s. These rapid, high-volume injections were facilitated by co-administration with recombinant human hyaluronidase PH20. The HVAI was assessed in previous preclinical studies in miniature pigs and in a Phase I clinical trial using the same devices (syringe pump and HVAI), test solution, and injection hardware, facilitating direct comparison between injection outcomes. Injection duration and injection site outcomes (swelling, induration, erythema, back-leakage) were measured in all studies. Injection force measurements with the syringe pump in pigs versus humans allowed for the calculation of a scaling factor to model injection duration in humans (90.8%) which was used to estimate an injection time of 27.5 s with this specific HVAI configuration. Observed injection duration between the two species were similar and not statistically different (30.0 s vs 27.9 s; p = 0.17). Swelling and induration were more significant in pigs than in humans (p < 0.01), while erythema scores tended to be higher in humans than in pigs (p < 0.05). Collectively, the miniature pig is a translatable model for subcutaneous injection that can generate useful predictions of injection times in human studies and de-risk clinical trials.
Indexed as
Identifiers
42060065What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.